TY  - JOUR
A1  - Wendel, Philipp
A1  - Reindl, Lisa Marie
A1  - Bexte, Tobias
A1  - Künnemeyer, Leander
A1  - Särchen, Vinzenz
A1  - Albinger, Nawid
A1  - Mackensen, Andreas
A1  - Rettinger, Eva
A1  - Bopp, Tobias
A1  - Ullrich, Evelyn
T1  - Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy
T2  - Cancers
N2  - The promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first ex vivo generated NK cell-enriched products utilized for adoptive immunotherapy. Over the past decades, various immunotherapies have been developed, including cytokine-induced killer (CIK) cells, as a peripheral blood mononuclear cells (PBMCs)-based therapeutic product, the adoptive transfer of specific T and NK cell products, and the NK cell line NK-92. In addition to allogeneic NK cells, NK-92 cell products represent a possible “off-the-shelf” therapeutic concept. Recent approaches have successfully enhanced the specificity and cytotoxicity of T, NK, CIK or NK-92 cells towards tumor-specific or associated target antigens generated by genetic engineering of the immune cells, e.g., to express a chimeric antigen receptor (CAR). Here, we will look into the history and recent developments of T and NK cell-based immunotherapy.
KW  - NK cell
KW  - T cell
KW  - CIK cell
KW  - NK-92
KW  - cell therapy
KW  - immune therapy
KW  - CAR-T cell
KW  - CAR-NK cell
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62467
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-624676
SN  - 2072-6694
N1  - The participating laboratories have been supported by the FCI and DKTK (to EU, PW,TBe), by the DFG (CRC/SFB 1292 and IRTG; to EU, TBe, LMR, NA, VS, TBo), by the German CancerAid (to EU, AM), the “Alfred and Angelika Gutermuth-Stiftung” (to EU), by “Menschen für Kindere.V.” (to EU) and MSNZ (to TBe).
VL  - 13
IS  - 6, art. 1481
SP  - 1
EP  - 24
PB  - MDPI
CY  - Basel
ER  -